Previous Close | 0.0450 |
Open | 0.0450 |
Bid | 0.0450 x 0 |
Ask | 0.0450 x 0 |
Day's Range | 0.0400 - 0.0450 |
52 Week Range | 0.0350 - 0.1750 |
Volume | |
Avg. Volume | 72,478 |
Market Cap | 3.485M |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings Date | Aug 12, 2024 - Aug 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious ...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.Cyt
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Services include advice on the structure of equity or debt capital financing and the identification of potential future investors. The Company intends to .